The Use of Human Epididymis 4 and Cancer Antigen 125 Tumor Markers in the Benign or Malignant Differential Diagnosis of Pelvic or Adnexal Masses

Basit Öğe Kaydı
dc.contributor.authorAltıntaş, Zehra Nihal Dolgun
dc.contributor.authorKabaca, Canan
dc.contributor.authorKarateke, Ateş
dc.contributor.authorİyibozkurt, Cem
dc.contributor.authorİnan, Cihan
dc.contributor.authorAltıntaş, Ahmet Salih
dc.contributor.authorKaradağ, Cihan
dc.date.accessioned2021-11-20T10:10:03Z
dc.date.available2021-11-20T10:10:03Z
dc.date.issued2017
dc.departmentFakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Kadın Hastalıkları ve Doğum Anabilim Dalıen_US
dc.description.abstractBackground: Ovarian cancer is one of the highest mortality cancers in gynaecology. Discrimination of benign masses from malignant ones may sometimes become a challenge for the clinician since there is not a reliable tumour marker, thus some unnecessary, highly morbid operations can be performed. Aims: To explore the efficacy of human epididymis 4 (HE 4) and cancer antigen 125 (CA 125) markers in differentiating malignant and benign pelvic masses of ovarian origin and to identify the cut-off points for those markers. Study Design: Prospective study. Methods: Fifty-one patients who were diagnosed and planned to undergo surgery for ovarian mass between June 2008 and December 2008 were enrolled into this study. Preoperative venous blood samples were taken and frozen for marker investigation and final diagnoses were concluded by histopathological examination. After recruitment of all cases CA 125 and HE 4 levels were evaluated. Results: The statistical analysis did not indicate any statistically significant difference between the CA 125 levels of the patients with malignant and benign adnexal masses (p=0.105). The HE 4 levels of the patients with malignant adnexal masses were higher at a statistically significant level compared to the patients with benign adnexal masses (p=0.002). For HE 4 tumour marker and at the cut-off point of >25 pM, sensitivity was 1, specificity 0.40, positive cut-off value 0.19, negative cut-off value 1, accuracy 0.47 and positive likelihood ratio 1.65. Conclusion: Human epididymis 4 is a better diagnostic tool than CA 125 in benign-malignant discrimination of adnexal masses. The cut-off value of 25 pmol/L for human epididymis 4 will contribute to providing proper guidance to patients with adnexal masses and applying the proper treatment method.en_US
dc.identifier.doi10.4274/balkanmedj.2016.0223en_US
dc.identifier.endpage162en_US
dc.identifier.issn2146-3123
dc.identifier.issn2146-3131
dc.identifier.issue2en_US
dc.identifier.pmid28418343en_US
dc.identifier.scopus2-s2.0-85016443786en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage156en_US
dc.identifier.trdizinid229738en_US
dc.identifier.urihttps://app.trdizin.gov.tr/makale/TWpJNU56TTRPQT09
dc.identifier.urihttps://hdl.handle.net/20.500.14551/5488
dc.identifier.volume34en_US
dc.identifier.wosWOS:000400660600010en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofBalkan Medical Journalen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240608_ID_Qen_US
dc.subjectCerrahien_US
dc.titleThe Use of Human Epididymis 4 and Cancer Antigen 125 Tumor Markers in the Benign or Malignant Differential Diagnosis of Pelvic or Adnexal Massesen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
5488.pdf
Boyut:
374.04 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Balkan Medical Journal
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu